DR.REDDY'S LABORATORIES LTD. - 500124 - Notice Of 38Th Annual General Meeting (AGM) And Annual Report 2021-22
Notice of 38th Annual General Meeting (AGM) and Annual Report 2021-2206-07-2022
06-07-2022
JB Pharma acquires four brands from Dr Reddy's Laboratories for 98.3 crore
This is the company's third acquisition in one financial year01-07-2022
Dr Reddy's: End to patent litigation case in US court
Case related to generic drugs for opioid dependence; Dr Reddy'swill receive $72 million30-06-2022
JB Chemicals gets board approval to acquire Dr Reddy's 4 brands for 98 cr
JB Chemicals & Pharmaceuticals on Thursday said its board has approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about Rs 98 crore. The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing. The company has inked a pact with Dr Reddy's Laboratories to acquire four of its brands -- Z&D, Pedicloryl, Pecef and Ezinapi -- for the India market, it added. All four brands are focused on the paediatric segment in the country with a total covered market size of Rs 1,800 crore as per IQVIA data, JB Chemicals & Pharmaceuticals said. The combined sales of these brands stood at around Rs 33 crore for FY 2021-22, it added. The acquisition, which will be funded primarily through long-term debt, will be completed in the next few working days, the drug firm stated.30-06-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Closure of Trading Window
The trading window for dealing in securities of the Company will be closed from Thursday, June 30, 2022, to Saturday, July 30, 2022 (both days inclusive).29-06-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ending On June 30, 2022.
DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 ,inter alia, to consider and approve To consider and approve the Unaudited Financial Results of the Company for the quarter ending on June 30, 2022.29-06-2022
Investor Day Transcript: Dr. Reddy's Laboratories
Investor Day with Dr. Reddy's Laboratories Management, Investors and Analysts on FY22 Performance and Outlook. Click pdf to read the full transcript. Management in attendance: G V Prasad – Co-Chairman & Managing Director Erez Israeli – Chief Executive Officer Parag Agarwal – Chief Financial Officer MV Ramana – Chief Executive Officer, Branded Markets Sanjay Sharma – Global Head of Manufacturing Archana Bhaskar – Chief Human Resources Officer Jayanth Sridhar – Global Head of Biologics Amit Agarwal – Head of Investor Relations & Analytics28-06-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Investor Day28-06-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F28-06-2022